Cover Image

Multimmune GmbH的產品平台分析

Multimmune GmbH - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 259369
出版日期 內容資訊 英文 20 Pages
Back to Top
Multimmune GmbH的產品平台分析 Multimmune GmbH - Product Pipeline Review - 2015
出版日期: 2015年07月08日 內容資訊: 英文 20 Pages

Multimmune GmbH是正在開發治療癌症用治療手法的生物醫藥品企業。

本報告提供Multimmune GmbH的藥劑開發平台的現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的藥物的評估等資訊。

Multimmune GmbH的基本資料

Multimmune GmbH概要

  • 主要資訊
  • 企業資料

Multimmune GmbH:R&D概要

  • 主要的治療範圍

Multimmune GmbH:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Multimmune GmbH:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Multimmune GmbH:藥物簡介

  • mi-TUMEX
  • mi-APO

Multimmune GmbH:開發平台分析

  • 各給藥途徑
  • 各分子類型

Multimmune GmbH:暫停中的計劃

Multimmune GmbH:總公司和子公司的所在地



Product Code: GMDHC07336CDB


Global Markets Direct's, 'Multimmune GmbH - Product Pipeline Review - 2015', provides an overview of the Multimmune GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Multimmune GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of Multimmune GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Multimmune GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Multimmune GmbH's pipeline products

Reasons to buy

  • Evaluate Multimmune GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Multimmune GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Multimmune GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Multimmune GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Multimmune GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Multimmune GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Multimmune GmbH Snapshot
    • Multimmune GmbH Overview
    • Key Information
    • Key Facts
  • Multimmune GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Multimmune GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Multimmune GmbH - Pipeline Products Glance
    • Multimmune GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Multimmune GmbH - Drug Profiles
    • ENKASTIM-ev
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ENKASTIM-iv
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mi-TUMEX
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mi-APO
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Multimmune GmbH - Pipeline Analysis
  • Multimmune GmbH - Pipeline Products by Route of Administration
  • Multimmune GmbH - Pipeline Products by Molecule Type
  • Multimmune GmbH - Dormant Projects
  • Multimmune GmbH - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Multimmune GmbH, Key Information
  • Multimmune GmbH, Key Facts
  • Multimmune GmbH - Pipeline by Indication, 2015
  • Multimmune GmbH - Pipeline by Stage of Development, 2015
  • Multimmune GmbH - Monotherapy Products in Pipeline, 2015
  • Multimmune GmbH - Preclinical, 2015
  • Multimmune GmbH - Discovery, 2015
  • Multimmune GmbH - Pipeline by Route of Administration, 2015
  • Multimmune GmbH - Pipeline by Molecule Type, 2015
  • Multimmune GmbH - Dormant Developmental Projects,2015

List of Figures

  • Multimmune GmbH - Pipeline by Top 10 Indication, 2015
  • Multimmune GmbH - Pipeline by Stage of Development, 2015
  • Multimmune GmbH - Monotherapy Products in Pipeline, 2015
  • Multimmune GmbH - Pipeline by Top 10 Molecule Type, 2015
Back to Top